Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19

Jianyu Lai, B.Med., M.P.H.[a,b], Jennifer German, Ph.D.[b], Filbert Hong, Ph.D.[b], S.-H. Sheldon Tai, Ph.D.[b], Kathleen M. McPhaul, Ph.D., M.P.H.[b], Donald K. Milton, M.D., Dr.P.H.[b] for the University of Maryland StopCOVID Research Group[*]

[a] Department of Epidemiology and Biostatistics, University of Maryland School of Public Health, College Park, Maryland, USA
[b] Public Health Aerobiology and Biomarker Laboratory, Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park, Maryland, USA

[*] Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive, College Park, MD 20742 email: dmilton@umd.edu; phone: 301-405-0389 (Alternate: Dr. Filbert Hong, at the same address, email fhong@umd.edu, phone: 301-405-4081)

Key Words: COVID-19; SARS-CoV-2; saliva; mid-turbinate swab; polymerase chain reaction

Running Title: Saliva Versus MTS for COVID-19 Detection

Key Points:

- Saliva is more sensitive in detecting symptomatic cases of COVID-19 than MTS early in the course of infection.
- Saliva performs best in the pre-symptomatic period.
- Saliva and MTS demonstrated high agreement making saliva a suitable and cost-effective COVID-19 screening tool.

Abstract

Background: Saliva is an attractive sample for detecting SARS-CoV-2 because it is easy to collect and minimally invasive. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs.

Methods: We recruited and followed close contacts of COVID-19 cases for up to 14 days from their last exposure and collected self-reported symptoms, mid-turbinate swabs (MTS) and saliva every two or three days. Ct values and frequency of viral detection by MTS and saliva were compared. Logistic regression was used to estimate the probability of detection by days since symptom onset for the two sample types.

Results: We enrolled 58 contacts who provided a total of 200 saliva and MTS sample pairs; 14 contacts (13 with symptoms) had one or more positive samples. Overall, saliva and MTS had similar rates of viral detection ($p=0.78$). Although Ct values for saliva were significantly greater than for MTS ($p=0.014$), Cohen's Kappa demonstrated substantial agreement ($\kappa=0.83$). However, sensitivity varied significantly with time relative to symptom onset. Early in the course of infection (days -3 to 2), saliva had 12 times (95%CI: 1.2, 130) greater likelihood of detecting viral RNA compared to MTS. After day 2, there was a non-significant trend to greater sensitivity using MTS samples.

Conclusion: Saliva and MTS specimens demonstrated high agreement, making saliva a suitable alternative to MTS nasal swabs for COVID-19 detection. Furthermore, saliva was more sensitive than MTS early in the course of infection, suggesting that it may be a superior and cost-effective screening tool for COVID-19.

Introduction

The U.S. Centers for Disease Control and Prevention (CDC) recommend the use of upper respiratory specimens, including but not limited to nasopharyngeal, mid-turbinate nasal, anterior nasal and saliva specimens for the initial diagnosis of COVID-19 [1]. Although nasopharyngeal swabs (NPS) are considered to be the standard for the detection of COVID-19 by most researchers, collection requires the use of trained professionals, can cause discomfort to the patients, and may pose greater risks to healthcare workers during sample collection [1–4]. Mid-turbinate swabs (MTS) are sometimes used as an alternative to NPS in an effort to reduce patient discomfort and occupational exposures to healthcare workers [4–6]. Compared to swab-based collection, saliva is even less invasive, more affordable, and can be self-collected with minimal or no supervision [1,7,8].

Existing studies focusing on the sensitivity of NPS compared to MTS, and NPS compared to saliva have produced contradictory results [2,4,9–11]. Few studies directly compare saliva and MTS specimens. Previous studies demonstrated that pre-symptomatic transmission results in higher secondary attack rates for both symptomatic and asymptomatic transmission [12,13]. However, most of the existing studies only looked at detection of symptomatic cases after symptom onset [2,4,9,10] and few looked at detection sensitivity starting with the pre-symptomatic period. Therefore, a study that conducts a direct comparison of MTS and saliva, including an assessment of sensitivity over time (starting during the pre-symptomatic period) is critical to identifying optimally sensitive methods for early detection and effective control of SARS-CoV-2 transmission.

The purpose of this study was to compare the sensitivity of MTS and saliva specimens for detecting SARS-CoV-2 by actively following close contacts of COVID-19 cases and collecting MTS and saliva samples for real-time reverse transcription polymerase chain reaction (RT-PCR) during their post-exposure quarantine period.

Methods

Study population

We analyzed MTS and saliva sample data from individuals who reported close contact with confirmed COVID-19 cases as part of the University of Maryland StopCOVID study [14] from May 2020 to April 2021.

Questionnaire and sample collection

Participants were followed every two or three days for up to 14 days from their last exposure or until SARS-CoV-2 was detected in their samples. If one or more of their screening samples became positive, results were confirmed by an appropriate clinical diagnostic test and they were recruited to participate in the exhaled breath aspect of the study that also involved the collection of saliva and MTS [14]. On each day of sample collection, participants answered an online questionnaire to update their current symptoms and medications. For those who reported having any symptom, they also reported their symptom onset date (i.e., “When did you begin to feel sick?”).

The symptoms checklist in the baseline and follow-up questionnaires, as previously described [14], included runny nose, stuffy nose, sneezing, sore throat, earache, malaise, headache, muscle

and/or joint ache, sweat/feverish/chills, nausea, loss of appetite, vomiting, abdominal pain or diarrhea, chest tightness, shortness of breath, and cough. Participants self-reported for each of these 16 symptoms on a scale of 0 to 3 (0 = "no symptoms," 1 = "just noticeable," 2 = "clearly bothersome from time to time, but didn't stop me from participating in activities," 3 = "quite bothersome most or all of the time and stopped me from participating in activities").

For saliva collection, participants were instructed to not eat or drink 30 minutes prior to the visit and then collect approximately 0.5-1 mL of saliva drooled into a plastic collection tube. For MTS collection, trained clinical staff inserted a mid-turbinate swab approximately 1.5-2 inches into one of the participants' nostrils, rotated once, and then withdrawn. This procedure was repeated in the other nostril for a total of two MTS per participant per visit.

Laboratory analyses

Saliva samples were processed using the SalivaDirect method [8] as previously described [14]. Briefly, 50 µL of individual saliva samples were treated with Proteinase K (New England Biolabs), heated at 95°C for 5 minutes, and kept at 4˚C. MTS from both nostrils were combined and processed as previously described [14]. Briefly, total nucleic acid was extracted from 200 µL of MTS with MagMax Pathogen RNA/DNA Kit (Applied Biosystems) on KingFisher Duo Prime (Thermo Fisher Scientific), following the manufacturers' protocols. The sample was eluted in 50 µL of Elution Buffer and kept at 4 °C. MS2 phage was spiked in each heat-treated saliva sample and extraction to control for extraction and PCR failure. RT-PCR was set up on the same day; each reaction consisted of 1X TaqPath 1-Step Master Mix, No ROX, 1X TaqPath COVID-19 Real Time PCR Assay Multiplex (both from Thermo Fisher Scientific), and 10 µL of heat-treated saliva or eluted nucleic acids. Each PCR plate contained a positive control provided in the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific) and a no template control. A positive sample was defined as having Ct (cycle threshold) values < 40 for at least two out of three SARS-CoV-2 targets (ORF1ab, N gene, and S gene)[15]. The average Ct values of all positive targets were used in the following analyses.

Statistical analyses

We analyzed only paired same-day saliva and MTS samples to ensure the comparability of the two samples. Group comparisons were made between participants having a positive result for either sample and those with both samples being negative. Continuous variables (age and BMI) were compared using t-test, and categorical variables were compared using Chi-square test (sex and chronic respiratory illness) and Fisher's exact test (age group, race, and ever smoker).

To compare the Ct values from saliva and MTS, we conducted paired t-test and Bland-Altman analysis, and calculated the coefficient of determination (i.e., R squared from linear regression) and Pearson correlation coefficient. The Chi-square test was used to explore the relationship between detection and sample types. Cohen's Kappa was calculated to demonstrate the degree of agreement between the two sample types.

For participants with a positive saliva or MTS sample, we used a generalized additive logistic model [16] to estimate and plot the probability of having a positive result by days since symptom onset for the two sample types. We also created a plot using the LOESS (locally weighted smoothing) method with 95% confidence interval for the change of Ct values by days since

147 symptom onset for the two sample types. Logistic regression was used to estimate the relative
148 odds of detection of SARS-CoV-2 in saliva over specified intervals since symptom onset.
149
150 All the analyses were carried out using RStudio and R (version 4.0.4) [17].
151

152 *Ethics statement*

153 This study was approved by the University of Maryland Institutional Review Board and the
154 Human Research Protection Office of the Department of the Navy. Electronically signed
155 informed consent was obtained from all participants and questionnaire data were collected and
156 stored with REDCap [18].
157

158 ## Results

159 We enrolled 58 individuals with known close contact with an active COVID-19 case. Contacts
160 provided a total of 200 saliva and MTS pairs. The number of days of sample collection per
161 participant ranged from one to seven. Among the contacts, 14 (24%) had at least one positive
162 sample including 11 with both positive saliva and MTS samples over the course of follow-up.
163 One contact had only positive saliva on 3 out of 3 samples (on days -3, 0, and 1 post symptom
164 onset) and 2 had only positive MTS samples; one was positive on 2 of 2 swabs (on days 7 and
165 10) and one on 1 of 5 swabs (day 21, negative on days 14, 17, 19, and 24). Most of the positive
166 participants (92.9%) were symptomatic, whereas only one (2.3%) participant from the test
167 negative group reported symptoms. Symptomatic participants were enrolled -3 to 14 days since
168 symptom onset and gave samples for up to 24 days from onset of symptoms. Symptoms were
169 mild across the follow-up period. One participant had an oral temperature ≥ 38 °C at the time of
170 sampling; three in total had temperatures ≥ 37.8 °C, and six in total had temperatures ≥ 37.5 °C;
171 all were in the positive group. No other significant differences were identified between the
172 positive and negative groups (Table 1).
173

174 *Viral RNA detection in and agreement between saliva and MTS*

175 Among 200 pairs of saliva and MTS samples we detected viral RNA in 32 (16%) of the saliva
176 and 29 (14.5%) of the MTS samples. The frequency of detection was similar for both sample
177 types (p=0.781) (Table S1). Cohen's Kappa demonstrated substantial agreement (κ=0.83) with
178 26 (14%) positive and 165 (82.5%) negative sample pairs (Table 2). The 14 participants who
179 became positive by either sample type during the follow-up period provided 41 saliva-MTS
180 sample pairs, among which 71% of MTS and 78% of saliva samples were positive (Table S2),
181 without respect to time since symptom onset. When focusing on positive participants, however,
182 the agreement was weak (κ=0.43 for all and κ=0.42 for those who were symptomatic) (Table S3a
183 and S3b).
184

185 *Comparison of Ct values between saliva and MTS*

186 Each RT-PCR reaction contained 10 µL of heat-treated saliva sample or RNA extracted from
187 MTS. Assuming no loss in the process, each reaction represented 7.78 µL of saliva sample or 40
188 µL of the MTS eluate. The Ct values for paired samples were highly correlated (rho = 0.84, r2 =
189 0.74, Figure 1a). The Ct values for saliva were on average slightly but significantly greater than
190 for MTS samples (mean difference = 0.64, p=0.01) among all 58 participants (Figure 1b and
191 Figure S1), partially reflecting the difference in their input amounts.
192

Relationship between days since symptom onset, sample types and probability of detection

The Ct values among the positive symptomatic participants increased over time (day -3 through 24), indicating decreasing viral load. Saliva tended to have lower Ct values compared to MTS from days -3 to 1.5, where MTS samples had lower Ct values thereafter (Figure 2A).

Among symptomatic participants who had one or more positive saliva or MTS samples, the probability (sensitivity) of detecting viral RNA in saliva samples was 91% (10/11) from day -3 to day 2 (Table 3), was 89% (16/18) from day 3 through 8, and declined significantly thereafter (Figure 2B and Figure S2). The probability of detecting virus in MTS samples from day -3 through day 2 was lower 45% (5/11), was 94% (17/18) from day 3 through 8, and then dropped off again. Early in the course of infection (days -3 through 2) saliva had 12 times the odds of being positive compared to MTS (Odds ratio = 12, 95% CI: 1.2, 130). Although there was a trend toward greater sensitivity using MTS than saliva samples after day 2 post onset of symptoms, the difference was not statistically significant (Table 3).

Asymptomatic case

Only one participant from our study population was an asymptomatic case. They provided one pair of saliva and MTS samples, both of which were positive, with an average Ct value of 25.8 for MTS and 34.7 for saliva (Table S4).

Discussion

Early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal swabs (MTS). We found that the optimal performance of saliva was in the pre-symptomatic period and was more sensitive than MTS before symptom onset. Several studies have shown that pre-symptomatic transmission plays a more important role than symptomatic and asymptomatic transmission in the spread of SARS-CoV-2 [12,13]. Furthermore, saliva tended to have lower Ct values compared to MTS from the pre-symptomatic period through the first few days post symptom onset. Together, these findings suggest that saliva may be the preferred sample for detecting SARS-CoV-2 early during the course of infection.

The CDC and the Infectious Disease Society of American recommendations for COVID-19 testing allow MTS, NPS, oral swabs, anterior nasal swabs, and saliva swabs as well as saliva.[1,19] Some studies have shown differences in the sensitivity between NPS and MTS. In older, more acutely ill populations, NPS appears to be more sensitive than MTS, especially later in the course of illness (greater than 7 days) [4,9]. In a study of ambulatory and symptomatic participants whose ages were more evenly distributed, NPS and MTS swabs were highly correlated with a mean of 7 days since onset of symptoms [20]. Congrave-Wilson et al., in agreement with the current study, found that saliva had the highest sensitivity in the first seven days post COVID-19 onset when using NPS as the reference [2]. Becker et al. compared the sensitivity of saliva and NPS for detecting COVID-19 in a convalescent cohort 8-56 days since first symptom and found that NPS performed better [21]. They also showed that saliva was about 30% less sensitive than NPS in a diagnostic cohort, however, days since symptom onset were not reported, so we cannot make direct comparison with our findings. Finally, a systematic review by Bastos et al. found that saliva had similar sensitivity to NPS and costs less [11].

Our findings have implications for improving public acceptance of COVID-19 testing, reducing the cost of mass COVID-19 screening, and improving the safety of healthcare workers who conduct testing. These findings are extremely important when considering large-scale screening of COVID-19 in schools and workplaces. In addition to its higher sensitivity in the early stage of the disease as demonstrated in our data, saliva has quite a few other advantages that make it an appealing screening tool. Saliva collection is less invasive and more acceptable to the general population [7,22]. One of the barriers hindering COVID-19 testing is people's fear of nasal swabs due to misinformation [23]. Also, the discomfort brought by nasal swabs may also reduce people's willingness to get tested regularly, especially among children [24,25]. With the use of saliva, screening in large groups with increased frequency may be more practicable. Saliva is cheaper than swab-based methods, especially if pooled samples are used [11,26]. Bastos et al. estimated that when sampling 100,000 individuals, using saliva saved more than $600,000 in comparison to using NPS [11]. These cost savings are especially important in the context of low resource settings.

Saliva collection is also safer for healthcare workers (HCWs). Amid the pandemic, one of the key concerns among HCWs is the occupational exposure to SARS-CoV-2 aerosols during some medical procedures [27]. The collection of nasal swabs introduces such exposure via the close interaction between patients and HCWs and by patients' coughing and sneezing as a result of the procedures [28]. In contrast, saliva is the only upper respiratory specimen suggested by the CDC that can be self-collected without supervision [1] and hence protects HCWs from directly contacting the patients when the samples are being collected. Given all these advantages of saliva compared to NPS, our findings further support the use of saliva for large-scale screening, especially of pre-symptomatic patients.

The current study has several limitations. The contacts enrolled in this study who eventually tested positive for SARS-CoV-2 developed mild, and in some cases, transient infections. Some of these mild (low viral titer) infections would not have been detected by less frequent testing protocols and may not have posed a risk for onward transmission. The sample size of those who tested positive is relatively small. Only one asymptomatic case was identified in our study so we could not compare the sensitivity of the two types of samples among asymptomatic COVID-19 cases. The evidence for using saliva to detect asymptomatic cases was mixed in previous studies [2,10] and further studies are needed to clarify this issue.

In conclusion, the use of saliva is preferable for testing pre-symptomatic populations. It is more acceptable to people, which reduces barrier to testing. It is also more cost effective for individuals to collect their own saliva rather than using highly trained professionals to collect NPS and/or MTS. Finally, self-collected saliva samples eliminate the exposure to aerosols produced by sneezing, coughing and gagging of patients undergoing NPS/MTS.

Funding

This work was supported by Prometheus-UMD, sponsored by the Defense Advanced Research Projects Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through agreement N66001-18-2-4015. This work was also supported by the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS)

Contract Number HHSN272201400008C, and the Centers for Disease Control and Prevention Contract Number 200-2020-09528. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or policy of these funding agencies and no official endorsement should be inferred.

This work was also supported by a grant from the Bill & Melinda Gates Foundation, and a generous gift from The Flu Lab (https://theflulab.org). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

None of the authors have a potential conflicting interest or funding source.

Acknowledgements

We thank all the other members of the University of Maryland StopCOVID Research Group for their efforts in recruiting participants and sample collection and processing: Oluwasanmi Oladapo Adenaiye, Barbara Albert, P. Jacob Bueno de Mesquita, Yi Esparza, Aaron Kassman, Michael Lutchenkov, Dewansh Rastogi, Maria Schanz, Isabel Sierra Maldonado, Aditya Srikakulapu, Delwin Suraj, Faith Touré, Rhonda Washington-Lewis, Somayeh Youssefi, Stuart Weston, Matthew Frieman, Mara Cai, Ashok Agrawala. We also thank Dr. Jamal Fadul and his clinic in College Park, Maryland, for assistance in recruiting study participants.

References

1. Centers for Disease Control and Prevention. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html. Accessed 12 October 2021.

2. Congrave-Wilson Z, Lee Y, Jumarang J, et al. Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection. JAMA **2021**; Available at: https://doi.org/10.1001/jama.2021.13967. Accessed 5 September 2021.

3. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic Review and Meta-analysis. Journal of Clinical Microbiology 59:e02881-20.

4. Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infect Control Hosp Epidemiol :1–3.

5. Chu CY, Marais G, Opperman C, et al. Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa. Lancet Infect Dis **2021**; 21:1354.

6. Yp T, R J, B H, et al. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. The New England journal of medicine **2020**; 383. Available at: https://pubmed.ncbi.nlm.nih.gov/32492294/. Accessed 25 October 2021.

7. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-CoV-2 detection. The Lancet Respiratory Medicine **2021**; 9:562–564.

8. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med **2021**; 2:263-280.e6.

9. Pinninti S, Trieu C, Pati SK, et al. Comparing Nasopharyngeal and Mid-Turbinate Nasal Swab Testing for the Identification of SARS-CoV-2. Clin Infect Dis **2020**; Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337631/. Accessed 19 March 2021.

10. Teo AKJ, Choudhury Y, Tan IB, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. Scientific Reports **2021**; 11:3134.

11. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis. Ann Intern Med **2021**; 174:501–510.

12. Bender JK, Brandl M, Höhle M, Buchholz U, Zeitlmann N. Analysis of Asymptomatic and Presymptomatic Transmission in SARS-CoV-2 Outbreak, Germany, 2020. Emerg Infect Dis **2021**; 27. Available at: https://wwwnc.cdc.gov/eid/article/27/4/20-4576_article.htm. Accessed 8 October 2021.

346 13. Qiu X, Nergiz AI, Maraolo AE, Bogoch II, Low N, Cevik M. The role of asymptomatic and
347 pre-symptomatic infection in SARS-CoV-2 transmission—a living systematic review.
348 Clinical Microbiology and Infection **2021**; 27:511–519.

349 14. Adenaiye OO, Lai J, de Mesquita PJB, et al. Infectious SARS-CoV-2 in Exhaled Aerosols
350 and Efficacy of Masks During Early Mild Infection. Clin Infect Dis **2021**; :ciab797.

351 15. ThermoFisher Scientific. TaqPath™ COVID-19 Combo Kit and TaqPath™ COVID-19
352 Combo Kit Advanced* Instructions for Use. Available at:
353 https://www.fda.gov/media/136112/download. Accessed 24 November 2021.

354 16. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med
355 Res **1995**; 4:187–196.

356 17. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria:
357 R Foundation for Statistical Computing, 2021. Available at: https://www.R-project.org/.

358 18. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
359 community of software platform partners. Journal of Biomedical Informatics **2019**;
360 95:103208.

361 19. Hanson KE, Caliendo AM, Arias CA, et al. The Infectious Diseases Society of America
362 Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clinical
363 Infectious Diseases **2021**; :ciab048.

364 20. Tu Y-P, Jennings R, Hart B, et al. Swabs Collected by Patients or Health Care Workers for
365 SARS-CoV-2 Testing. N Engl J Med **2020**; 383:494–496.

366 21. Becker D, Sandoval E, Amin A, et al. Saliva is less sensitive than nasopharyngeal swabs for
367 COVID-19 detection in the community setting. medRxiv **2020**; :2020.05.11.20092338.

368 22. Byrne RL, Kay GA, Kontogianni K, et al. Saliva offers a sensitive, specific and non-invasive
369 alternative to upper respiratory swabs for SARS-CoV-2 diagnosis. medRxiv
370 **2020**; :2020.07.09.20149534.

371 23. Yangchen S, Ha S, Assan A, Tobgay T. Factors Influencing COVID-19 Testing: A
372 Qualitative Study in Bhutan. In Review, 2021. Available at:
373 https://www.researchsquare.com/article/rs-885659/v1. Accessed 9 November 2021.

374 24. Clifford V, Curtis N. Saliva testing for severe acute respiratory syndrome coronavirus 2 in
375 children. Clinical Microbiology and Infection **2021**; 27:1199–1201.

376 25. Leach AJ, Stubbs E, Hare K, Beissbarth J, Morris PS. Comparison of Nasal Swabs with
377 Nose Blowing for Community-Based Pneumococcal Surveillance of Healthy Children.
378 Journal of Clinical Microbiology **2008**; 46:2081–2082.

379 26. Watkins AE, Fenichel EP, Weinberger DM, et al. Increased SARS-CoV-2 Testing Capacity
380 with Pooled Saliva Samples. Emerg Infect Dis **2021**; 27.

381 27. Nicholson PJ, Sen D. Healthcare workers and protection against inhalable SARS-CoV-2
382 aerosols. Occupational Medicine **2021**; 71:118–120.

383 28. Qian Y, Zeng T, Wang H, et al. Safety management of nasopharyngeal specimen collection
384 from suspected cases of coronavirus disease 2019. Int J Nurs Sci **2020**; 7:153–156.

385
386

387 Tables

388

389 Table 1. Characteristics of the study population

		Never positive	Positive for MTS or saliva	All participants
Number of participants		44	14	58
Number of sample pairs		159	41	200
Number of days of sample collection per participant, median (range)		4 (1, 7)	3 (1, 6)	3 (1, 7)
Female, N (%)		20 (46)	8 (57)	28 (48)
Age, mean ± SD		26.5 ± 15.5	27.3 ± 13.8	26.7 ± 15
Age group, N (%)				
<18		2 (4)	1 (7)	3 (5)
18-45		38 (86)	11 (79)	49 (84)
>45		4 (9)	2 (14)	6 (10)
White, N (%)		30 (68)	11 (79)	41 (71)
BMI, mean ± SD		25.6 ± 4.9	25.2 ± 4.4	25.5 ± 4.7
Chronic respiratory illness [a], N (%)		17 (39)	5 (36)	22 (38)
Ever smoker, N (%)		1 (2)	1 (7)	2 (3)
Ever symptomatic [b], N (%)		1 (2)	13 (93)	14 (24)
Symptomatic participants	Days since symptom onset at enrollment, median (range)	2 (-)	3 (-3, 14)	2.5 (-3, 14)
	Overall days since symptom onset of sample collection, median (range)	6.5 (2, 12)	5 (-3, 24)	5 (-3, 24)
	Loss of taste/smell, N (%)	0	2 (15)	2 (14)
	Median upper [c] respiratory symptoms (IQR)	3 (1.2, 6.2)	2 (0, 3)	2 (0.2, 3)
	Median lower respiratory symptoms (IQR)	0 (0, 0)	0 (0, 1)	0 (0, 1)
	Median systemic symptoms (IQR)	0.5 (0, 1.8)	0 (0, 1.2)	0 (0, 1.8)
	Median gastrointestinal symptoms (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)
	Temperature, mean Celsius ± SD	37 ± 0.3	37.2 ± 0.5	37.2 ± 0.4

390 [a] Chronic respiratory illness = volunteers with any Chronic obstructive pulmonary disease,
391 Asthma, Other lung diseases.
392 [b] Group comparison, $p<0.05$.

[c] Symptoms at the time of each sample collection visit. Sixteen individual symptoms were rated from 0 to 3. Systemic (max score of 12) = malaise + headache + muscle/joint ache + sweats/fever/chills; Gastrointestinal (max score of 12) = loss of appetite + nausea + vomit + diarrhea; Lower Respiratory (max score of 9) = chest tightness + shortness of breath + cough; Upper Respiratory (max score of 15) = runny nose + stuffy nose + sneeze + earache + sore throat.

402 Table 2. Viral RNA detection in paired saliva and MTS samples from all participants (N=58) [a]

Saliva Positive	*MTS Positive* No	*MTS Positive* Yes	***Total***
No	165	3	168
Yes	6	26	32
Total	171	29	200

403 [a] κ=0.83
404

405 Table 3. Sensitivity of saliva and MTS and relative odds of detection of SARS-CoV-2 in saliva
406 by day since symptom onset among 13 mildly symptomatic contacts of known cases

Days since symptom onset [a]	**Saliva Positive/N (Sensitivity %)**	**MTS Positive/N (Sensitivity %)**	**Odds Ratio Saliva:MTS**	**p-value**
-3 through 2	10/11 (91)	5/11 (45)	12 (1.2, 130)	0.04
3 through 8	16/18 (89)	17/18 (94)	0.47 (0.037, 6)	0.55
9 through 24	5/11 (45)	6/11 (55)	0.7 (0.13, 3.8)	0.67

407 [a] Days since symptom onset inclusive of the start and end day

408

Figure Legends

Figure 1. Association between Ct values of saliva and MTS samples among 58 participants and 400 samples

A. Scatter plot of Ct values of saliva and MTS

B. Bland-Altman plot for comparison of saliva and MTS

Figure 2. The change of Ct values and probability of testing positive by days since symptom onset. Data are for MTS and saliva samples from 13 participants who provided a total of 40 pairs of samples and had one or more samples positive for SARS-CoV-2 RNA.

A. Change of Ct values by days since symptom onset,

B. Probability of being tested positive by days since symptom onset estimated from a generalized additive logistic model.

427 Figures

428



429


A
B
Average Ct value
Probability of testing positive
Days since symptom onset
Days since symptom onset
Generalized Additive Logistic Models
MTS
Coef SE z p
Intercept 0.96 0.39 2.5 0.013
edf Chi.sq p
s(Days since onset) 2.6 7.3 0.078
Saliva
Coef SE z p
Intercept 1.7 0.52 3.2 0.0014
edf Chi.sq p
s(Days since onset) 1 8.7 0.0033
Sample Type MTS Saliva